21 60 Vol. 21 No

函館市_絵で見てわかる

70 75 26 2 27 1 2 3 4 5 6 7 8 9 4 6 6 6 8 10 10 10 10 12 21 21 22 26 28 30 32 34 36 2 3 70 75 701 28 75 6575 7075 28 75 3 4 5 75 65 26 28 75 65 75 1 1 70 7075 2 2 2 1 260 90 210 18 9012 160 18 100 183

A B 1.A B A B 2.A B A B 3.A

1 1. 2.WHO 3. 4. 5. 2 2.0mg/kg / 1. 2. 3. 4. 5. 3 1. 90 2. 3. 4. 5. 4 1. 2. 3. 4. 5. 1 21 5 1. 2. 2050 61 3. 1 4. 5. 6 1. ----------- 2. ---- 3. ------ 4. -------- 5. --------- 7 A B 1.A B------------------A

20－121

20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150

Microsoft Word - 高橋＿国試講習会2006m.doc

2006 19 150 20 200 19 80 2 70 1 45 1 1 30 20 105 2 40 1 1 31 95 2 25 1 1 32 1. 2. 3. 4. 5. 1 [] 25 12.5% 2006/3 6 2 1 2 3 7 A a b c d 11 e B a b c d C a b c D a b E a b c d 2 15 16 17 18 19 20 2001 2002

橡サプリメント.PDF

Vol.13,No.1,2004 1 Feb.200Vol.13 No.1 Vol.13,No1,2004 2 70) ph H2 P450 P450 70) Vol.13,No.1,2004 ALDH N- H2 P-450 H2 ADH ADH ADH CYP ADH 200mg/dl ADH P-450CYP CYP CYP 17)18) N- 1 48g ADH 3 Vol.13,No1,2004

橡200006youbou.PDF

ボトックス注用

2018 5 21 2017 1220 5 8 7 1 2 2 9 50 100 22100AMX00488 22100AMX00489 2009 9 2009 9 2009 2 1997 4 2016 6 2018 5 1989 12 1A 2 1 2 3 2 4 5) 1 100 1 2 3 4 A 1 50 50 0 45mg 0 25mg 100 100 0 9mg 0 5mg A 1 4mL

[] 1

0 [] 1 [] 2 [] 2010 22 0% 20% 40% 60% 80% 100% 15.4 65.2 10.8 8.6 12,000 2010 22 2020 32 2030 42 2040 52 2015 27 14.3 63.3 12.3 10.1 10,000 2020 32 13.2 63.0 11.9 11.9 8,000 2025 37 12.3 62.9 10.6 14.2

13年度主要施策の成果について

....

2030 2 Vol. 22 No. 32000 1/2 EE F FAF 60E 1970 40 25FIP 1995 503cx 60 10M5 Vol. 22 No. 32000 3 carpal tunnel syndrome entrapment neuropathy cm 4 Vol. 22 No. 32000 5 Vol. 22 No. 32000 10 2- microglobulin

　　　　　　　　　　　　　　　　　　　　　　　　　2009,3,1

200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3

日歯雑誌（Ｈ２２・７月号）ＨＰ用／ｐ０６‐１６　クリニカル①　田崎

NewsLetter-No2

, TV,

untitled

19 11 13 300 18 3 31 1300mg 4 6 C 15 H 22 FN 3 O 6 359.35 + -1-5--β-D--5--1,2--2- -4- 19 11 13 300 18 3 31 A B B A 30 1 2 21 7 1 1 1.31m 2 900mg 1.31m 2 1.64m 2 1,200mg 1.64m 2 1,500mg B 30 1 2 14 7 1

untitled

. 23 3 2 1 2 3 21 21 22 9 1 23 18 4 5 6 5 40 20 7 1 1 8 9 10 11 12 50cm 13 10 11 14 2011 3 11 15 16 ml mm tel 079-557-0039 & fax 079-557-1888 17 248-240- 98-48- 170-98- 98- ml 85-1,085-18 19 20 21 22 23

Vol.171 2004.9.15 14 100 5 10 15 52 53 55 1 7 55 58 63 3 26 53 3 6 9 2 3 6 9 6 52 53 55 3 9 5 1 7 10 14 4 12 8 11

Vol.170 2004.9.9 9 17 9 17 1000 8 10 9 17 14:00 17:00 30 28 Vol.171 2004.9.15 14 100 5 10 15 52 53 55 1 7 55 58 63 3 26 53 3 6 9 2 3 6 9 6 52 53 55 3 9 5 1 7 10 14 4 12 8 11 9.17 10 15 38 51 53 55 6 2

土地改良523号.indd

untitled

1 Q A 82% 89% 88% 82% 88% 82%

M1 TSH T 3 T 4 2 T 1 2 Plummer 3 TSH TSH K 5 7 TSH TSH Plummer TSH TSH TSH TSH T 4 T 3 TSH T 4 T 3 TSH TSH or Plummer Plummer or a) 1. 2. 3. b) 1. T 4 T 3 2. TSH 0.1 U/ml 3. TSH TRAb TSAb 4. 1) a) 1

まえがき

JAAS0012006 1 -------------------------------------------------------------------------------------------------------- 1 2 --------------------------------------------------------------------------------------------------------

untitled

労働法総論講義(2・完)

173 174 175 176 .... 177 ............ NHK NHK.. NHK.................. 178 ........ 179 180 181 182 183 .. 184 185 186 187 .............. 188 .. 189 .. 190 .. 191 192 193 .. 194 195 196 .............. 197

サクラの木につく毛虫の観察

0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2

24 11 10 24 12 10 30 1 0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2 23% 29% 71% 67% 6% 4% n=1525 n=1137 6% +6% -4% -2% 21% 30% 5% 35% 6% 6% 11% 40% 37% 36 172 166 371 213 226 177 54 382 704 216

10 117 5 1 121841 4 15 12 7 27 12 6 31856 8 21 1983-2 - 321899 12 21656 2 45 9 2 131816 4 91812 11 20 1887 461971 11 3 2 161703 11 13 98 3 16201700-3 - 2 35 6 7 8 9 12 13 12 481973 12 2 571982 161703 11

3 4 6 7 8 9 10 12 14 2 3

3 4 6 7 8 9 10 12 14 2 3 POINT 4 5 3053 1323 4 7 6 1 1 4 7 Yamada N. et al : Int J Cardiol. 98, 409-411, 2005 6 7 POINT 0 20 40 60 80 100 60 80 Ota M. et al: Heart Vessels. 17, 7-11,2002 40 60 20 50 15

-1- -2- -3- -4- 14mm17mm -5- -6- -7- L=15.4km L=13.4km L=6.5km 200m3 L=3.4km 2m3 200m3 723 494 4,681ha 7,441-8- () -9- -10- -11- -12- -13- 23 JR JR -14- -15- km -16- -17- -18- -19- -20- -21- -22- 2-23-

エディロールカプセルインタビューフォーム

2012 4 5 873112 2008 () 1 0.5g 0.5g 0.75g 0.75g JAN EldecalcitolJAN 2011 1 21 2011 3 11 2011 4 11 TEL0120-591-818 03-3985-5599 8:3017:00 http://www.taishotoyama.co.jp/ 20124 http://www.info.pmda.go.jp/

() 2

1 () 2 2 4 3 6,500 4 5 2 6 A B A B A B A B - A B 7 8 A B A B A B 9 JR JR 10 11 6 5 12 17 6 13 14 B A A B A B A B 2 1 8 15 8 16 17 9 18 3 4 5 mm mm 19 2 20 3 6 7 11 12 13 14 18 4 3 2 1 21 3 12 13 14 16

I

I II 1 2 3 4 5 6 7 8 9 10 11 Rp.1) 50mg 3 3 14 Rp.2) 2.5mg 2 14 Rp.1) 2.5mg 3 2 2:1 14 Rp.) 15g 1 3 28 Rp.2) 50 600mg 1 2 28 12 Rp.1) CR 20mg 1 1 1 14 Rp.2) R 200 1 2 14 Rp.3) 3 1 3 14 Rp.1) 2.5mg 0.4

Vol. 4, No

1 0.005 71 2 0.005 72 3 0.005 73 4 0.005 74 5 0.005 KRM 75 6 0.005 76 7 0.005 77 8 0.005 78 9 0.005 79 10 0.005 80 11 0.005 TS 81 12 0.005 TOA 82 13 0.005 83 14 0.005 84 15 0.005 NS 85 16 0.005 86 17 0.005

訪問入浴Ｑ＆Ａ PDFファイ ル　httpwww.care-mirai.commiraihomehelpe_buth.html.docx

4 450kg500kg 185cm 95kg 100kg 185 ( ) Vision , 40 8/138/15 1/11/3 1 13,000 11,700 9,500 3,500 13,000 11,700 9,500 3,500 http://www.care-mirai.com 1 37 38 1 1,000PPM soda premium 1,100ppm http://www.care-mirai.com/mirai/carbonated.html

国試過去問集.PDF

I 89 16 3 130 ab c AMPcAMP a 1 --- b c --- 2 --- --- 3 --- --- 4 --- --- 5 --- --- camp camp Ca 2+ β1 camp A camp camp A β1 p.156 β p.146 b. p.157 p135 (ANP) p157 c PDE-III p.157 p.157, 183 PDE C Ca PDE-III

<4D F736F F D B BA908593B98AC782AB82E593E082CC88C091538AC7979D82C98AD682B782E992868AD495F18D908F912E646F63>

12 62 1800 14 3 11 14 4 14 4 30 ... 1... 1... 1... 2... 5... 6... 7... 10... 13... 18... 19 21 22 24 27 28 31 32 33... 34... 35... 37 2 1,650mm () H=2,500W=2,000 460m 750m 500m 42.1m 1.15m () 100% 80%

“÷Œò›ï46

46 1 1 50.1 2 34 kgkg100 XCT100cm 2 2005 1100cm 2 85 cm90 cm 5 5 1 2 6OSCE OSCE 7 8 9 13 14 16 17 17 20 18 19 22 23 25 19 26 6 BMI 4.0g/ml 6 2 7 RIA EIA 8 3.10.3 ng/ml 7.91.2 ng/ml 2 7401620 2002 9 11

1 2 3 4 5 68g 9g 2g 0.2mg 0.8mg 316kcal 316cal 326kcal 326cal 6 010 3035 15 5355 30 120 20 7 8 9 10 11 () () () 12 1 3 1 5 1 80kcal 20 30 20 30 1 9 7.5 13 7.58.5 910.5 1213.5 11.512.5 14 15 79 23 1520

1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)

2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)

misasa_vol35

家庭系パソコンの回収再資源化にかかる論点

1 134 1212 134 2 1 137 1212 (1) 12 12,102 40.2 4,865 2-1 12 21,497 2-2 50.1 2-3 1 kg 2 12 2-1 13 12% 2-1 (2) 2-2 4 4 7 2-3 4 (3) 13.8 2-4 46 10 80 3 3 4 3 2-5, 2-6 13 9 2-7 18 2 2 8 5,000 30 25% 25 2 2

1990 1010 21 (1)(2) (3) (4) Vol. 21 No. 111999 3

201980Japan as number one 21American as number one 20 198020 19701980 1980 1990 2 Vol. 21 No. 111999 1990 1010 21 (1)(2) (3) (4) Vol. 21 No. 111999 3 SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS

2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1

成人病（１）.PDF

日本皮膚科学会雑誌第121巻第11号

β Clin Rheumatol Arthritis Rheum Am J Cardiol J Rheumatol J Rheumatol Arthritis Rheum Arthritis Rheum Arthritis Rheum Rheumatology Oxford Rheumatology Oxford Br J Dermatol Arch Dermatol Ann Rheum Dis

表1.eps

Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol

g 51 52

10 12 A 12 C 12 13 13 13 13 16 16 18 18 18 23 23 23 23 23 A 24 25 25 26 28 28 30 32 38 38 41 42 43 10 43 11 45 48 48 120g 51 52 12 3 12 3 350g 120g 1 7 10 260g 90g 90g 30g 9 11 2 gg1 g 1 120g 10 1 12 6

HPLC 1M KH 2 PO 4 ph ml Anthranilic acid: AnA 600 ml ml AnA 1.0 ml / min Anthranilic acid= PRESSURE 140 kgf / cm 2

15 10-1-3. 1. HPLC 1M KH 2 PO 4 ph 3.0 50 ml Anthranilic acid: AnA 600 ml 1-1. 350 ml AnA 1.0 ml / min Anthranilic acid=137.14 PRESSURE140 kgf / cm 2 TOSOH TSK-GEL ODS- 80 Ts 1) mg / ml AnA in (φ4.6 250

0.01mg/ ç 0.01 mg/ ç 0.01 mg/ ç 0.01 mg/ ç 0.05 mg/ ç 0.05 mg/ ç 0.01 mg/ ç 0.01 mg/ ç 0.0005mg/ ç 0.0005mg/ ç 0.02 mg/ ç 0.02 mg/ ç 0.002 mg/ ç 0.002 mg/ ç 0.004 mg/ ç 0.004 mg/ ç 0.02 mg/ ç 0.02 mg/

「若年不安定就労・不安定住居者聞取り調査」報告書

2008 3 2006 2007 3 19 6 7 5,400 2007 4 5 19 94 1 2 2007 5 i 2007 6 12 100 100 1 2 2008 3 ii 1960 1990 iii = 1990 = = iv 5 5 v & = 2 24 = 1990 10 vi vii i iii 1 3 1.1.............................................

ml ml ml mg ml ml mm mm mm mm mm mm mm mm mm mm mm ml mmhg mmhg ml Acetylcholine ml mg mm mm mm mm mm mm ope ++ Uribe Davis S H S S : : : : : : : : : G

住まい・まちづくり活動事例集

3 H15 1982 1988 5 H16.31 1 1 1 246 26 3 2003 11 21,417/ 65 17.91% 16.62%1.29 246 2 1 12 1246 5008026 30080 3 200803 120060 2 20013 1 1 21 11 19821988 199112003 13 1988 1 1991 28 3 1991 1993 1992 1 1995

untitled

~ ~ ~ ~ ~ 22 14 10 50cm 2124 15 21 29.5 11, 12 12 20 4040 10 60 60 10 20 20 11 ç ç çç 6070 ç ç çç p. ç çç 4.5cm2.5cm 25 http://www.crdc.gifu-u.ac.jp/edsoftol/water/

からだにeヘルシーレシピ 高血圧

We b e 3,5 00 7day 1. 2. & 3. 1 C O N T E N T S 2.6 0 1 0 5 0 7 1 0 9 17 2 2 2 3 CHECK&POINT! 2 5 24 1 2 7 e 2 9 e 3 1 webe 3 3 6 12 18 24 6 16 16g 111 1 6 1 2010 2010 18 20 3,970 18 1 400 2.6 01 02 140mmHg

食肉の知識

A5_Catalog-US-JN_ indd

66 22 g 13 g 8 g 5 g 7500 IU 150% 300 mg 600 IU 100 IU 80 mcg 3 mg 3.5 mg 40 mg 4 mg 500 mcg 12 mcg 300 mcg 20 mg 1000 mg 150 mcg 400 mg 15 mg 105 mcg 2 mg 2 mg 180 mcg 125 mcg 15 mg 3.6 g ** 3.8 g **

2

19 8 1970 20 10 4 1

19 8 1970 20 10 4 1 IgE 1960 % 1970 20%, 1990 40% 1998 70% 20 IgE 21 90% IgE IgE (%) 70 60 50 40 30 20 10 0 1970 1975 1980 1985 1990 1995 2000 2005 1. 2005 10 2 30 IgE 2. 3 1. B IgE T IgE IgE IgE 2 T IgE

untitled

237 238 G 8-1 239 240 G - 241 242 G - 243 244 G 8-2 245 246 G - 247 248 G 8-3 900 600 249 250 G 8-3 251 252 G 8-5 253 254 G 8-5 255 700 700mm800mm850mm 256 G - 257 258 G 8-7 259 35 7.5 100 100 8 260 G

2 2

1 1 143km 2,860km 2 1 2 2 3 3 4 4 5 6 1516 2,050mm 1,700mm 350mm 3,000mm 6 7 23km 7 8 8 9 9 10 10 11 0.53m 713cm 1.52.5m 20m 712cm 25mm 15cm 11 12 22cm 15cm 37.5cm 45cm 45cm 20cm 5276cm 2642cm 12 13 13

12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36

IF 1 MR 63 2 IF 10 3 IF 2IF IF IF 3IF A4 9 IF IF IF 11 1 IF IF 4IF IF MR IF IF MR Drug Safety Update IF

2008 2 3 87269 IF19989 100g 700g 30g SucrosePovidoneIodine 1999 3 15 1999 7 9 2000 5 IF 2008 2 IF 1 MR 63 2 IF 10 3 IF 2IF IF IF 3IF A4 9 IF IF IF 11 1 IF IF 4IF IF MR IF IF MR Drug Safety Update IF 1981

( ) 1

1.8.2 Page MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) / Candida glabrata (25) 0.25 / 0.5 Candida guilliermondii a) (2)

1.8.2 Page1 1.8.2 96% 2002 40 B 1 123 (1) in vitro 1) in vitro C. glabrata C. krusei 1 2 19951997 3 1999 2002 MIC MIC 2 1.8.2 Page2 1 19951997 MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) 0.016 /

NAD11 00 1 1-1 1-2 1-3 5V 1-4 1 2 3 4 5 6 7 8 1 2 3 4 5 6 1-5 1 2 3 1 2 3 4 1-6 1 2 3 1-7 1-8 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 1 2 3 4 5 1

/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1

11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1

2001 2003 2005 2006 2007 2008

2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65

BAANs理論に基づく保健指導プログラム暫定版

WHO 4 5 10% L- -3 RNA L - 1960-3 RNA mrna Bio Activating Advanced Nutrients BAANs BAANs BAANs BAANs L- (NO) -3 EPA, DHA) RNA RNA DNA TNF- PAI-1 ( ) BAANs 40 50% 20% 1Kg 7,000Kcal 50Kcal 11 50Kcal

日本医師会雑誌第131巻第10号

B C 100 12 11 13 3 C 4 C Q&A B C 54 B B B B Q&A B B HBV 20 HBV B B B B HBV HBV HBV HBV 2 HBV HBV HBV A HBV HBV HBV HBV HBV Q37 HBV HBV HBV 1015 B B B Q51 B HBV B B HBV B HBV HBV HBV B B B HBV B HBV HBV

Microsoft Word - 14_LCMS_アクリルアミド

3--2-3-Iodo-2-propynyl butylcarbamate (IPBC) Carbamic acid, butyl-, 3-iodo-2-propynyl ester Iodocarb CAS 55406-53-6 C 8 H 12 NO 2 I C (g/cm 3 ) (mmhg) log P ow 281.09 (280.9910) 64 68 1.51 1.57 (20 C)

橡アロマセラピー症状別処方例.PDF

1 1 92 E 100ml 1 2 2 1 93 0.5m 10ml 100ml 1 2 3 2 52 0. l 2 4 3 27 3 1 1 3 3 4 5 3 2g 2 3 1 1 1 10ml 3 4 6 3 29 2 2 2 10ml 3 3 4 7 3 30 2 1 2 10ml 3 3 4 8 3 31 1 1 1 1 3 60 10 10 3 2 4 10ml A 2 3 61 20

437“ƒ

et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer

無印良品 2012 自転車 カタログ

26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417

1 1 1 11 25 2 28 2 2 6 10 8 30 4 26 1 38 5 1 2 25 57ha 25 3 24ha 3 4 83km2 15cm 5 8ha 30km2 8ha 30km2 4 14

3 9 11 25 1 2 2 3 3 6 7 1 2 4 2 1 1 1 11 25 2 28 2 2 6 10 8 30 4 26 1 38 5 1 2 25 57ha 25 3 24ha 3 4 83km2 15cm 5 8ha 30km2 8ha 30km2 4 14 60 m3 60 m3 4 1 11 26 30 2 3 15 50 2 1 4 7 110 2 4 21 180 1 38

紀要No.9_006王_CS.indd

1 2 3 4 5 87 9 2009 1937.1 6 1937.1 2 1937.3 1937.9 73 1941.6 77 1941.10 27 1943.9 1943.10 1944.12 1946.12 1947.1 5 1948.4 L 1949.9 10 1950.10 1953.1 1953.12 1956.5.16 1956.6 1966.9 30 1966.10 1967.4 1967.9

untitled

20 2 14 18 10 16 1 1.0mg 0.035mg 2 1 20 2 14 18 10 16 1 1 1 52 1 1 21 7 28 1 29 2 1 20 1 24 18 10 16 1 1 21 7 28 1 29 1 NET 1.0mg EE 0.035mg *NET *NET 1999 2007 *NET *NET 88 NSAIDs GnRH GnRH NSAIDs 20

(1) (2) (3) (4) (5) (6) (7) 4 (8) (9) () LAN 1 2 3 ( ) () () () 30 20 5 5 450 450 5 5 30 10 20 15 36 30 6 6 450 450 6 6 36 8 30 14 50 35 20 20 450 450 20 20 50 8 35 14 100 70 20 20 450 450

152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1

152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1 JAS 1-2 1-2 112 13 1-11-13 100870mg 100830mg11000 1100020.002 2 50 100 2 100 500 2 100 109252165 4514782 7 2.0kg 2-19220.05kg0.2kg

2

IF MR 63 IF 10 IF IF IF IF A4 IF IF IF 11 IF IF IF IF MR IF IF MR Drug Safety Update() IF

200823 877122 IF19989 HYDROPHILIC OINTMENT 1g 250mg 200mg 120mg 60 40mg 10mg 1mg 1mg HydrophilicOintment 200821 19518 19977 IF20082 IF MR 63 IF 10 IF IF IF IF A4 IF IF IF 11 IF IF IF IF MR IF IF MR Drug

untitled

16 23 16 8 10 16 18 21 23 17 2 23 18 7 31 97 89 H18.7.31 97% 89% 19,034 13,590 97% 89% 5,444 96% 86% 96% 86% 13,590 H18 99% 96% 2,535 100% 99% H18 99% H18 2,909 93% 41% 26% :2 :20 :25 18% 14% 84% 45% 100%

untitled

1999年3月作成(新様式第１版)　

200622 19989 871313 1mL4mg JAN oxybuprocaine hydrochloridejan 2002621 20037 4 19667 1 FAX 2005 10 29607 05 1 63 () 103 2 3 49 111 4 Drug Safety Update 1. -------------------------------------1 2. -----------------------1

レジャー産業と顧客満足の課題

1 1983 1983 2 3700 4800 5500 3300 15 3 100 1000 JR 4 14 2000 55% 72% 1878 2000 5 ( ) 22 1,040 5 946 42 15 25 30 30 4 14 39 1 24 8 6 390 33 800 34 34 3 35 () 37 40 1 50 40 46 47 2 55 4.43 4 16.98 40 55

ケイセントラ_製品情報概要_H1-4_収載_新発売

DIC 135-627 12 CONTENTS 34 32 33 1 2 K 34 3 4 5 12 12 18 24 3 31 31 31 33 KVKA K K VKA VKA K - PT-INR KC S 1996VKA VKA 3 KK CS 33 34 35 35 35 36 36 K 32 33 213 4VKA 12VKAFDA Kcentra 42 217 1 in vitro 1

薬物治療学分野症例シリーズ７

( 4 ) 1-2 1-2 (New Engl J Med, 2004) I, II III () IV NCI-CTC CTC Version 2.0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ( ( 21 22 23 CTC Version 2.0 24 瘙 Non-steroidal anti-inflammatory

™¹ficŒ«“O1

234 50cm

234 50cm () 1 10 2 3 4 1 5 6 2 2 1 7 ( ー ) っ ー っ 8 1 2 10 10 2m 4m 6m 15m 457-2472 585-1154 9 10 2 60 2 100 RC SRC 30 80 500 1 500 500 ) 10 B b A 2 A B 2m 457-2473 585-1154 11 20m a 2m 3 3 1m 75cm 120cm

Microsoft Word - 表紙資料２－４

(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)

食事編_表1_4_0508

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 5 2 5 24 () () () () () 1 1 150 50 50 1 1 ( 15,000 ) 150 ( 15,000 ) 100 50 50 1 1 ( 6,000 ) 150 ( 6,000 ) 100 50 50 1 1 150 1 1 150 100 0.25

50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH

3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-

ｱﾙｶﾘｲｵﾝ水ではじめよう

56cm 1 15 1960 2 8 2 2 1 2008 1992 2 1992 2 3562mm 3773mm 2 1980 1991 2008 2007 2003 5 2 3 2003 2005 2008 2010 2005 2008 2012 2010 2012 4 7 4 5 2 1975 1994 8 2008 NPO 2 2010 3 2013 2016 3 2008 2009 14